by NeOnc Technologies | Aug 6, 2024 | Media Articles
Main > Archives for NeOnc Technologies In The News | August 6, 2024 > USA Today Puts The Spotlight On NeOnc’s Dr. Thomas Chen. WESTLAKE VILLAGE, Calif., August 6, 2024 — NeOnc Technologies Holdings, Inc.’s, CEO and CSO Dr. Thomas Chen was...
by NeOnc Technologies | Aug 5, 2024 | Press Releases
Main > Archives for NeOnc Technologies Press Releases | August 5, 2024 > NeOnc Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with...
by NeOnc Technologies | Jul 24, 2024 | Press Releases
Main > Archives for NeOnc Technologies Press Release | July 24, 2024 > NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212 NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’...
by NeOnc Technologies | Jul 12, 2024 | Media Articles
Main > Archives for NeOnc Technologies Press Release | July 12, 2024 > LA Weekly Puts The Spotlight On NeOnc Technologies Holdings, Inc. Non-Invasive Drug Delivery Platform WESTLAKE VILLAGE, Calif., July 12, 2024 — NeOnc Technologies Holdings, Inc., was...
by NeOnc Technologies | Jun 26, 2024 | Press Releases
Main > Archives for NeOnc Technologies Press Release | June 26, 2024 > NeOnc Technologies Completes $18.5 Million Financing NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel...